ABN 84 117 391 812
CONSOLIDATED INTERIM FINANCIAL REPORT
FOR THE HALF-YEAR ENDED
31 DECEMBER 2020
Contents
Page | |
Directors' Report | 2 |
Auditor's Independence Declaration | |
4 | |
Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income | 5 |
Condensed Consolidated Statement of Financial Position | 6 |
Condensed Consolidated Statement of Cash Flows | 7 |
Condensed Consolidated Statement of Changes in Equity | 8 |
Notes to the Condensed Consolidated Financial Statements | 9 |
Directors' Declaration | 20 |
Independent Auditor's Review Report | |
21 |
This interim financial report does not include all the notes of the type normally included in an annual financial report. Accordingly, this interim report is to be read in conjunction with the annual report for the year ended 30 June 2020 and any public announcements made by Capitol Health Limited during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001.
Capitol Health Limited
Page 1
The Directors present their report together with the financial report of Capitol Health Limited ("Company") and its controlled entities (the "Group") for the half-year ended 31 December 2020, and the auditor's report thereon.
Directors
The Directors of the Company at any time during the half-year and up to the date of this report are:
Mr Andrew Demetriou
Non-Executive Director and Chairman
Mr Justin Walter
Managing Director and Chief Executive Officer
Mr Richard Loveridge
Non-Executive Director
Ms Nicole Sheffield Non-Executive Director
Financial Review
The Group recorded a profit for the half-year ended 31 December 2020 of $6.2 million.
o Operating revenue increased 5.9% to $85.3 million over the prior corresponding period. This increase was despite a second Covid-19 lockdown in Victoria and was driven by revenue from organic growth initiatives, re-indexation of Medicare rebates, and newly acquired businesses;
o Profit before Finance Costs, Depreciation and Amortisation and Income tax (EBITDA) increased 41.4% from $16.0 million to $22.6 million, as a result of the increased revenues over the period, cost containment, continuation of the JobKeeper program to the end of September 2020 and reduced transaction and restructure costs.
o Operating EBITDA (EBITDA prior to non-operating Transaction and restructure costs and the Revaluation/(impairment) of financial assets) increased 50.1% from $17.7 million to $26.6 million with the impairment entirely due to the movement in the AUD:USD exchange rate on the Group's investment in Enlitic (denominated in USD).
o The Operating EBITDA margin (Operating EBITDA as a percentage of Revenue) improved significantly to 31.1% compared to the previous comparable period of 22.0%. This improvement in margin reflects the implementation of strategic plan initiatives and continual focus on cost control.
o With the extension of Covid-19 lockdown in Victoria management continued to maintain tight control over the cost base of the business particularly focusing on matching staff levels and clinic operating hours to patient demand
o The Group was a recipient of the JobKeeper program during the period. The Group received $5.8 million in funding net of payment of wage to-ups in line with government policy to retain highly trained medical professionals and support staff during the lockdown period in Victoria and for the reduced demand in services.
o Transaction and restructure costs of $1.5 million compared to $1.7 million in prior comparable period.
o Net finance costs decreased 12.5% over the corresponding prior period to $1.7 million reflecting interest savings on a reduced level of borrowings from the prior period.
o The business cashflow relief on income taxes that the Group availed itself of were all settled within the period.
o The effective income tax rate for the period was 42.6% compared to 34.2% in the previous comparable period as a result of the impact of by the unrealised foreign exchange loss on the Enlitic investment.
Capital Management Initiatives
During the half-year to 31 December 2020 the Group did not undertake any new capital management initiatives and the share buy-back facility was not utilised over this period.
Events Occurring after the Reporting Period
Subsequent to the end of the Reporting Period:
Acquisition
On 1 February 2021 the Group completed the acquisition of the business and assets of Direct Radiology, which operates diagnostic imaging clinics in Fairfield, Monbulk and South Melbourne in Victoria.
The consideration for the acquisition amounted to $12.65 million and was funded from cash reserves, existing bank debt facilities and $0.65 million in issued shares in the Company. The shares are to be held in voluntary escrow until 31 August 2023 and are subject to achieving a revenue target in FY23.
Dividend
The Company declared an interim dividend for the half-year ended 31 December 2020 of 0.5 cents per share (31 December 2019: 0.5 cents) with the maximum dividend payable of $5.1 million (31 December 2019: $3.8 million).
Other than the above, there have been no other matters or circumstances occurring subsequent to the end of the half-year that has significantly affected, or may significantly affect, the operations of the Group, the results of these operations, or the state of affairs of the Group in subsequent financial years.
Auditor's Independence Declaration
The auditor's independence declaration is set out on page 4 of the consolidated interim financial report and forms part of the Directors report for the half-year ended 31 December 2020.
Rounding of Amounts
The Company is of a kind referred to in ASIC Corporations (Rounding in Financial/Directors' Reports) Instrument 2016/191 and therefore the amounts contained in this report and in the financial report have been rounded to the nearest thousand dollars, or in certain cases, the nearest dollar.
Signed in accordance with a resolution of the Directors made pursuant to Section 306(3) of the Corporations Act 2001.
On behalf of the Directors
____________________________
Justin Walter
Managing Director and Chief Executive Officer Melbourne, Victoria
23 February 2021
Auditor's Independence Declaration
Deloitte Touche Tohmatsu ABN 74 490 121 060
550 Bourke Street
Melbourne VIC 3000
GPO Box 78
Melbourne VIC 3001 Australia
Tel: +61 3 9671 7000
Fax: +61 3 9671 7001www.deloitte.com.au
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited ("DTTL"), its global network of member firms, and their related entities (collectively, the "Deloitte organisation"). DTTL (also referred to as "Deloitte Global") and each of its member firms and related entities are legally separate and independent entities, which cannot obligate or bind each other in respect of third parties. DTTL and each DTTL member firm and related entity is liable only for its own acts and omissions, and not those of each other. DTTL does not provide services to clients. Please seewww.deloitte.com/aboutto learn more.
Liability limited by a scheme approved under Professional Standards Legislation.
Member of Deloitte Asia Pacific Limited and the Deloitte Network
Capitol Health Limited
Page 4
Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income for the Half-Year Ended 31 December 2020
Notes | $000 | $000 | |
Statement of Profit or Loss | |||
Revenue | 4 | 85,305 | 80,554 |
Wages, contractor costs and salaries | (45,684) | (49,796) | |
Occupancy costs | (2,218) | (2,415) | |
Medical equipment and consumable supplies | (4,687) | (4,422) | |
Service costs | (6,162) | (6,228) | |
Transaction and restructure costs | (1,490) | (1,676) | |
Revaluation/(impairment) of financial assets | 6 | (2,416) | - |
Profit before Finance Costs, Depreciation and Amortisation, | |||
and Income Tax | 22,648 | 16,017 | |
Depreciation and amortisation | (10,070) | (9,970) | |
Profit before Finance Costs and Income Tax | 12,578 | 6,047 | |
Net finance costs | 5 | (1,712) | (1,957) |
Profit before Income Tax | 10,866 | 4,090 | |
Income tax expense | (4,629) | (1,397) | |
Profit for the Half-Year | 6,237 | 2,693 | |
Attributable to: | |||
Equity holders of the parent | 6,274 | 2,693 | |
Non-controlling interests | (37) | - | |
6,237 | 2,693 | ||
Basic Earnings per share (cents) | 14 | 0.61 | 0.35 |
Diluted Earnings per share (cents) | 14 | 0.59 | 0.34 |
Other Comprehensive Income | |||
Profit for the Half-Year | 6,237 | 2,693 | |
Net gain/(loss) on interest rate derivative, net of income tax | 53 | (137) | |
Other Comprehensive Income, net of income tax | 53 | (137) | |
Total Comprehensive Income for the Half- Year | 6,290 | 2,556 | |
Attributable to: | |||
Equity holders of the parent | 6,327 | 2,556 | |
Non-controlling interests | (37) | - | |
6,290 | 2,556 |
31 Dec 2020
31 Dec 2019
The Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income is to be read in conjunction with the accompanying notes.
Condensed Consolidated Statement of Financial Position as at 31 December 2020
31 Dec 2020 | 30 Jun 2020 | ||
Notes | $000 | $000 | |
Assets | |||
Cash and cash equivalents | 19,048 | 13,763 | |
Trade and other receivables | 4,606 | 5,493 | |
Other financial assets | 6 | 262 | 277 |
Other assets | 1,540 | 767 | |
Total Current Assets | 25,456 | 20,300 | |
Plant and equipment | 40,159 | 40,820 | |
Right-of-use asset | 9 | 57,656 | 54,729 |
Intangible assets | 7 | 117,358 | 117,949 |
Other financial assets | 6 | 19,722 | 22,138 |
Other receivables | 362 | 630 | |
Deferred tax asset | 5,510 | 5,741 | |
Total Non-Current Assets | 240,767 | 242,007 | |
Total Assets | 266,223 | 262,307 | |
Liabilities | |||
Trade and other payables | 14,666 | 16,967 | |
Lease liabilities | 9 | 9,406 | 9,640 |
Employee benefit liabilities | 11,729 | 10,828 | |
Income tax liability | 3,922 | 2,751 | |
Total Current Liabilities | 39,723 | 40,186 | |
Borrowings | 8 | 17,000 | 17,000 |
Lease liabilities | 9 | 55,796 | 52,702 |
Other financial liability | 10 | 4,884 | 3,698 |
Provisions | 1,340 | 1,340 | |
Employee benefit liabilities | 817 | 852 | |
Deferred tax liability | 2,030 | 2,490 | |
Total Non-Current Liabilities | 81,867 | 78,082 | |
Total Liabilities | 121,590 | 118,268 | |
Net Assets | 144,633 | 144,039 | |
Equity | |||
Issued capital | 11 | 146,340 | 145,776 |
Reserves | 12 | 1,608 | 2,694 |
Accumulated losses | (3,501) | (4,654) | |
Equity Attributable to Owners of the Parent | 144,447 | 143,816 | |
Non-controlling Interests | 186 | 223 | |
Total Equity | 144,633 | 144,039 |
The Condensed Consolidated Statement of Financial Position is to be read in conjunction with the accompanying notes.
Condensed Consolidated Statement of Cash Flows for the Half-Year Ended 31 December 2020
Operating Activities |
Receipts from customers |
Payments to suppliers and employees |
Interest received |
Interest and other finance charge on borrowings |
Interest on lease liabilities |
Income tax (paid)/refunded |
Net cash flows from operating activities |
Investing Activities |
Purchase of plant and equipment |
Payments for business acquisitions, investments |
including transaction costs |
Net cash flows (used in) investing activities |
Financing Activities |
Payments in respect of share buy-back and costs |
Proceeds on exercise of options |
Proceeds of secured loans |
Payment of dividend |
Payment of dividends to non-controlling interests |
Cash payment of lease liabilities |
Net cash flows from financing activities |
Net increase/(decrease) in cash and cash equivalents |
Cash and cash equivalents at beginning of the period |
Cash and cash equivalents at end of the period |
31 Dec 2020 | 31 Dec 2019 | |
Notes | $000 | $000 |
85,470 | 81,575 | |
(56,031) | (65,337) | |
4 | 14 | |
(676) | (791) | |
(1,004) | (1,003) | |
(3,620) | 59 | |
24,143 | 14,517 | |
(3,782) | (5,330) | |
(1,579) | (8,008) | |
(5,361) | (13,338) | |
- | (10) | |
197 | - | |
- | 5,000 | |
(8,997) | (3,842) | |
(92) | - | |
(4,605) | (4,176) | |
(13,497) | (3,028) | |
5,285 | (1,849) | |
13,763 | 7,330 | |
19,048 | 5,481 |
The Condensed Consolidated Statement of Cash Flows is to be read in conjunction with the accompanying notes.
Condensed Consolidated Statement of Changes in Equity for the Half-Year Ended 31 December 2020
Accumulated
Non-
Issued CapitalReserves
Profits/ (Losses)
Sub-Total
Controlling Interests
Total Equity
Balance at
1 July 2020
Profit for the half-year
Other Comprehensive Income for the half-year
Total Comprehensive Income
Transactions with Equity Holders Exercise of options
Conversion of issued options/rightsPut option from sale/acquisition of business
Share issue costs Dividend paid
Allocation of share-based employee costs
Total Transactions with Equity Holders
Balance at
31 December 2020
145,776 | 2,694 | (4,654) | 143,816 | 223 | 144,039 |
- - | - 53 | 6,274 - | 6,274 53 | (37) - | 6,237 53 |
- | 53 | 6,274 | 6,327 | (37) | 6,290 |
198 400 | - (400) | - - | 198 - | - - | 198 - (983) (34) (5,121) 244 |
- (34) - | (983) - - | - - (5,121) | (983) (34) (5,121) | - - - | |
- | 244 | - | 244 | - | |
564 146,340 | (1,139) 1,608 | (5,121) (3,501) | (5,696) 144,447 | - 186 | (5,696) 144,633 |
Balance at
1 July 2019
Profit for the half-year Other Comprehensive Income for the half-year
107,632 -1,374 -6,627 2,693
115,633 2,693
--115,633 2,693
- (137)
-(137)
Total Comprehensive Income Transactions with Equity Holders Share buy-back and costs Dividend paid
-
(137)
2,693
2,556
- -(137) 2,556
(10)
-
-
Allocation of share-based employee costs
- -
- (3,842)
(10) (3,842)
- - -
(10) (3,842)
348
-
348
348
Total Transactions with Equity Holders
-(10)
Balance at
31 December 2019
107,622
348 1,585
(3,842)
(3,504)
(3,504)
5,478
114,685
-
114,685
The Condensed Consolidated Statement of Changes in Equity is to be read in conjunction with the accompanying notes.
1. Reporting Entity
Capitol Health Limited (the "Company") is a company incorporated and domiciled in Australia. Capitol
Health Limited is a company limited by shares which are publicly traded on the Australian Securities Exchange. The consolidated interim financial report of the Company for the half-year ended 31 December 2020 comprises the Company and its subsidiaries (together referred to as the "Group").
The consolidated annual financial report of the Group for the year ended 30 June 2020 may be viewed on the Company's website:https://www.capitolhealth.com.au/reports-and-presentations
2. Basis of Preparation
This consolidated interim financial report is a general purpose financial report prepared in accordance with the Australian Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Act 2001.
The consolidated interim financial report does not include all of the information required for a full financial report and should be read in conjunction with the consolidated annual financial report of the Group for the year ended 30 June 2020. It is also recommended that the consolidated interim report be considered together with any public announcements made by the Group in accordance with continuous disclosure obligations under the Corporations Act 2001 and ASX listing rules.
The accounting policies and methods of computation adopted in the preparation of the half-year financial report are consistent with those adopted and disclosed in the annual financial report for the year ended 30 June 2020, except as noted in 2 iii) below.
The consolidated interim financial report was approved by the Directors on 23 February 2021.
i)Going Concern
The financial statements have been prepared on a going concern basis. For the half-year ended 31 December 2020, the consolidated entity made a profit of $6.2 million (31 December 2019: $2.7 million) and had net current liabilities of $14.3 million (31 December 2019: $19.9 million).
The directors have considered the following factors in determining the appropriateness of the going concern basis of preparation in the financial statements:
a) the consolidated entity has sufficient working capital to enable it to meet its objectives and financial obligations. Net available funding available through its secured banking facilities totals $154 million.
b) the consolidated entity generated net operating cash inflow for the half-year ended 31 December 2020 of $24.1 million (31 December 2019: $14.5 million).
Accordingly, the consolidated interim financial report has been prepared on a going concern basis, which contemplates the continuity of normal business activities and the realisation of assets and settlement of liabilities in the ordinary course of business.
ii)Comparative Figures
Where applicable comparative amounts have been adjusted to conform to changes in presentation in the current half-year.
2. Basis of Preparation (continued)
iii) New accounting standards and interpretations
The Group has adopted all of the new revised or amending Accounting Standards and Interpretations issued by the Australian Accounting Standards Board (AASB) that are mandatory for the current reporting period. Any new, revised or amending Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.
The Directors of the Group do not anticipate that the adoption of any of the amendments not yet adopted will have a material impact in future periods on the financial statements of the Group.
3. Significant Accounting Estimates, Assumptions and Judgements
The preparation of the consolidated interim financial report requires management to make judgements, estimates and assumptions that affect the reported amounts in the consolidated financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements and estimates on historical experience and on other various factors it believes to be reasonable under the circumstances, the results of which form the basis of the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates. Revisions to accounting estimates are recognised in the period in which the estimate is revised and in any future periods affected.
In preparing the consolidated interim financial report, the significant judgements made by management in applying the Groups' accounting policies and the key source of estimation uncertainty were consistent with those made for the consolidated financial report as at and for the year ended 30 June 2020.
4. Revenue
The Group solely operates within Australia and accordingly is only in one geographic market and only has one product and service category:
31 Dec 2020 31 Dec 2019 $000 $000
Major service category
Diagnostic imaging services | 85,244 | 80,419 |
Other operating revenue | 61 | 135 |
Total Revenue | 85,305 | 80,554 |
Revenue is recognised when the imaging service is rendered, and payment is either rebated via Medicare or payable on date of service.
5. Net Finance Costs
31 Dec 2020 | 31 Dec 2019 | |
$000 | $000 | |
Interest income | 6 | 13 |
Interest on borrowings | (633) | (875) |
Establishment fee | (13) | - |
Interest rate swap | (68) | (83) |
Lease interest | (1,004) | (1,003) |
Other interest | - | (9) |
(1,712) | (1,957) | |
Capitol Health Limited |
6. Other Financial Assets
31 Dec 2020 | 30 June 2020 | |
$000 | $000 | |
Current | ||
Rental bonds - held to maturity | 262 | 277 |
Non-current | ||
Investment in unlisted entity | 19,722 | 22,138 |
Movement | ||
Fair value - opening balance | 22,138 | 20,408 |
Investment during the period | - | 3,006 |
Revaluation/(impairment) of financial assets | ||
Unrealised foreign exchange gain/(loss) | (2,416) | 343 |
Impairment charge | - | (1,619) |
Fair value - closing balance | 19,722 | 22,138 |
The investment in unlisted entity is a level 3 financial asset as defined in 2.6.4 Fair Value Measurement of the 30 June 2020 Annual Report.
7. Intangible Assets
At 1 July 2020
Adjustment re prior year acquisitions Amortisation charge
At 31 December 2020
Cost value
Goodwill
Accumulated amortisation & impairment Total at 31 December 2020
$000 | $000 | $000 | $000 |
109,722 34 - | 1,258 - - | 6,969 - (625) | 117,949 34 (625) |
109,756 | 1,258 | 6,344 | 117,358 |
109,756 - | 1,258 - | 8,318 (1,974) | 119,332 (1,974) |
109,756 | 1,258 | 6,344 | 117,358 |
Brands and TrademarksReferrer RelationshipsTotal
Goodwill $000
At 1 July 2019
Acquisition of entities and businesses (net) Adjustment re prior year acquisitions Amortisation charge
97,304 12,399 19 -Brands and Trademarks $000
762 496 - -Referrer Relationships $000
Total $000
3,928 101,994 3,796 16,691 (27) (8) (728) (728)
At 30 June 2020
Cost value
Accumulated amortisation & impairment Total at 30 June 2020
109,722 109,722 - 109,722
1,258 1,258 - 1,258
6,969 117,949
8,318 119,298
(1,349) 6,969
(1,349) 117,949
7. Intangible Assets (continued)
The Group has performed an assessment of impairment indicators at the end of the reporting period, following the full impairment testing that was conducted at 30 June 2020. There were no indicators of impairment identified that required an impairment test to be conducted at the end of the reporting period.
8. Borrowings
31 Dec 2020 | 30 June 2020 | |
$000 | $000 | |
Non-current | ||
Bank borrowings | 17,000 | 17,000 |
17,000 | 17,000 |
The Group complied with all applicable financial covenant requirements for the half-year ended 31
December 2020.
9. Leases
31 Dec 2020 | 30 June 2020 | |
$000 | $000 | |
Current | ||
Lease liabilities | 9,406 | 9,640 |
9,406 | 9,640 | |
Non-current | ||
Lease liabilities | 55,796 | 52,702 |
55,796 | 52,702 |
i) Reconciliation of movement of Right-of-use asset for half-year ended
PropertyEquipment
Leases
LeasesTotal
At 1 July 2020
New leases entered into during the period Remeasured and modified leases Terminated leases
Amortisation charge
At 31 December 2020
Cost value
Accumulated amortisation
Total at 31 December 2020
$000 | $000 | $000 |
53,211 5,220 409 (86) (4,316) | 1,518 1,930 84 (23) (291) | 54,729 7,150 492 (109) (4,607) |
54,437 | 3,219 | 57,656 |
66,463 (12,026) | 3,952 (733) | 70,415 (12,759) |
54,437 | 3,219 | 57,656 |
9. Leases (continued)
i) Reconciliation of movement of Right-of-use asset for half-year ended (continued)
At 1 July 2020 | (54,803) |
Interest expense | (851) |
New leases entered into during the period | (5,220) |
Remeasured and modified leases | (284) |
Terminated leases | 51 |
Loss on modification/termination | (12) |
Cash payments | 4,149 |
At 31 December 2020 | (56,970) |
Current | (7,523) |
Non-current | (49,447) |
Total at 31 December 2020 | (56,970) |
Capitol Health Limited |
ii) Reconciliation of movement of lease liability for half-year ended
Property | Equipment | Total |
Leases | Leases | |
$000 | $000 | $000 |
Equipment | ||
Leases | Total | |
$000 | $000 | |
(7,539) | (62,342) | |
(153) | (1,004) | |
(1,930) | (7,150) | |
(85) | (369) | |
14 | 65 | |
- | (12) | |
1,461 | 5,610 | |
(8,232) | (65,202) | |
(1,883) | (9,406) | |
(6,349) | (55,796) | |
(8,232) | (65,202) |
At 1 July 2019
New leases entered into during the period Leases acquired on acquisition Remeasured and modified leases Amortisation charge
At 30 June 2020
Cost value
Accumulated amortisation Total at 30 June 2020
52,939 4,756 2,121 1,400 (8,005) | 1,988 - - 75 (545) | 54,927 4,756 2,121 1,475 (8,550) |
53,211 | 1,518 | 54,729 |
61,216 (8,005) | 2,063 (545) | 63,279 (8,550) |
53,211 | 1,518 | 54,729 |
Property
Leases
$000
9. Leases (continued)
ii) Reconciliation of movement of lease liability (continued)
Property | Equipment | Total | |
Leases | Leases | ||
$000 | $000 | $000 | |
At 1 July 2019 | (52,939) | (8,899) | (61,838) |
Interest expense | (1,605) | (363) | (1,968) |
New leases entered into during the period | (5,981) | - | (5,981) |
Leases acquired on acquisition | (2,121) | (815) | (2,936) |
Remeasured and modified leases | (175) | (75) | (250) |
Covid-19 rent relief | 380 | - | 380 |
Cash payments | 7,638 | 2,613 | 10,251 |
At 30 June 2020 | (54,803) | (7,539) | (62,342) |
Current | (7,212) | (2,428) | (9,640) |
Non-current | (47,591) | (5,111) | (52,702) |
At 30 June 2020 | (54,803) | (7,539) | (62,342) |
10. Other Financial Liabilities | |||
31 Dec 2020 | 30 June 2020 | ||
$000 | $000 | ||
Non- Current | |||
Other financial liabilities | 4,884 | 3,698 |
Other financial liabilities, in respect of the put and call options in relation to the non-wholly owned entities, have been valued at fair value in accordance with AASB 132 Financial Instruments: Presentation.
A financial liability of $1.2 million has been recognised in the period in respect of a new put option.
11. Issued Capital
Issued Capital | ||
30 June 2020 | ||
Number | ||
of shares | $000 | |
Balance at 1 July | 768,444,825 | 107,632 |
Exercise of options | - | - |
Share placement and share purchase plan | 248,996,426 | 40,000 |
Shares issued on acquisition | 6,901,313 | - |
Share issue costs | - | (1,499) |
Share buy-back | (1,745,370) | (357) |
Conversion from Share Option Reserve | - | - |
Balance at end of period | 1,022,597,194 | 145,776 |
31 Dec 2020 | 30 June 2020 |
$000 | $000 |
146,340 | 145,776 |
31 Dec 2020 Number of shares $000 | |
1,022,597,194 1,000,000 - - - 1,502,566 | 145,776 198 - - (34) 400 |
1,025,099,760 | 146,340 |
The Company does not have authorised capital or par value in respect of its issued shares.
The holders of ordinary shares are entitled to receive dividends as declared from time to time and are entitled to one vote per share at meetings of the Company. All shares rank equally with regards to the Company's residual assets.
Options and Performance Rights
The Company operates an incentive plan referred to as the Capitol Health Limited Employee Incentive Option Plan. The table below summarises the number of options and performance rights that were outstanding, their weighted average exercise price as well as the movements during the half-year:
Balance at 1 July | 32,839,827 | 28.96 |
Granted | 2,385,280 | - |
Exercised | - | - |
Forfeited | (1,744,765) | - |
Balance at end of period | 33,480,342 | |
Represented by: | ||
Options | 29,400,000 | 28.96 |
Performance rights | 4,080,342 | - |
Balance at end of period | 33,601,382 | 33,480,342 |
Capitol Health Limited | Page 15 |
Number 33,480,342 6,966,102 (2,502,566) (4,342,496)
31 Dec 2020 | 30 June 2020 |
Weighted | Weighted |
average | average |
exercise | exercise |
price | price |
Number (cents) |
(cents) 28.96 24.06 (19.70) (30.06)
33,601,382
12. Reserves
Interest
Balance at 1 July 2020 Exchange differences on translation of foreign subsidiaries Interest rate derivative movement | - - | (53) 53 | 2,107 - | 640 - | 2,694 53 |
Option Valuation Transferred on Exercise | - | - | (400) | - | (400) |
Put options from sale/purchase | - | - | - | (983) | (983) |
Allocation of share-based employee costs | - | - | 244 | - | 244 |
Movement for the financial year | - | 53 | 156 | (983) | 1,086 |
Balance at 31 December 2020 | - | - | 1,951 | (343) | 1,608 |
Balance at 1 July 2020 | - | (53) | - | - | (53) |
Interest rate derivative movement | - | 53 | - | - | 53 |
Balance at 31 December 2020 | - | - | - | - | - |
rate | |||
derivative | Option | Other | Total |
$000 | $000 | $000 | $000 |
- | 1,383 | - | 1,374 |
- | - | - | 9 |
(53) | - | (53) | |
2,070 | 2,070 | ||
- | - | (1,430) | (1,430) |
- | 724 | - | 724 |
(53) | 724 | 640 | 1,320 |
(53) | 2,107 | 640 | 2,694 |
Other Comprehensive Income (OCI) Items, net of tax: | |||
At 31 December 2020 | Interest | ||
rate | Retained | ||
derivative | Option | Earnings | Total |
$000 | $000 | $000 | $000 |
Interest | |||
rate | Retained | ||
derivative | Option | Earnings | Total |
$000 | $000 | $000 | $000 |
- | - | - | (9) |
(53) | - | - | (53) |
- | 9 | ||
(53) | - | - | (53) |
Currency translation $000
Balance at 1 July 2019
Exchange differences on translation of foreign subsidiaries
Interest rate derivative movement
Fair value of shares issued on acquisition Put options from sale/purchase Allocation of share-based employee costs Movement for the financial year Balance at 30 June 2020
At 30 June 2020
Balance at 1 July 2019
Interest rate derivative movement Foreign exchange translation differences Balance at 30 June 2020
(9)
9 - - - 9 -
Currency translation $000
Currency translation $000
(9)
-
9
-
13. Dividends
Fully franked dividends were declared during the financial period as follows:
31 Dec 2020 | 30 Jun 2020 | |
$000 | $000 | |
FY19 Final Dividend paid 0.5 cents per share on 23 October 2019 | - | 3,842 |
FY20 Interim Dividend paid 0.5 cents per share on 23 October 2020* | - | 3,877 |
FY20 Final Dividend paid 0.5 cents per share on 23 October 2020 | 5,121 | - |
5,121 | 7,719 |
*The payment of the FY20 interim dividend declared for the half-year ended 31 December 2019 was deferred from its initial payment date of 23 March 2020 until 23 October 2020.
Since the end of the half-year to 31 December 2020, the Directors have declared an FY21 interim dividend of 0.5 cents per share which is not recognised as a liability at 31 December 2020.
The Dividend Reinvestment Plan (DRP) is currently suspended.
14. Earnings per Share (EPS)
Basic EPS is calculated by dividing the profit for the half-year attributable to ordinary equity holders of Capitol Health Limited by the weighted average number of ordinary shares outstanding during the half-year.
Diluted EPS is calculated by dividing the profit for the half-year attributable to ordinary equity holders of the parent (after adjusting for outstanding options) by the weighted average number of ordinary shares outstanding during the half-year plus the weighted average number of ordinary shares that would be issued on conversion of all the dilutive potential ordinary shares into ordinary shares.
The following table reflects the profit and share data used in the basic and diluted EPS calculations:
31 Dec 2020 31 Dec 2019
$000 $000
Profit attributable to ordinary equity holders of the parent: | 6,274 | 2,693 |
Weighted average ordinary shares used as the denominator in | Number | Number |
calculating: | ||
Basic earnings | 1,024,254,107 | 768,415,482 |
Effect of dilution from share options and performance rights | 31,931,921 | 32,022,306 |
Diluted earnings | 1,056,186,029 | 800,437,788 |
Earnings per share - Continuing operations: | Cents | Cents |
Basic | 0.61 | 0.35 |
Diluted | 0.59 | 0.34 |
On 1 February 2021 a total of 2,347,752 fully paid ordinary shares were issued to the vendors of Direct Radiology which are the subject of a voluntary escrow until 31 August 2023.
Other than this, there have been no other transactions involving ordinary shares or potential ordinary shares between the reporting date and date of the authorisation of these financial statements.
15. Business combinations - Summary of acquisitions
Combinations for this reporting period
The Group finalised the accounting of the acquisition of Fowler Simmons Radiology during the half-year ended 31 December 2020. At 30 June 2020 the group provisionally accounted for goodwill of $14.5 million. There were no new acquisitions during the period.
Date of acquisitionBusiness Name
StatePurchase consideration $000
Net Assets Acquired $000
GoodwillNote Reference
$000
29 February 2020
Fowler Simmons RadiologySouth Australia
$16,620
2,260
14,360
i)
i) The Group acquired 90% of the issued share capital of Adrad Investments Pty Ltd which in turn holds 100% interest in
Adelaide Radiology Pty Ltd trading as Fowler Simmons Radiology. The fair value of net assets acquired include the plant and equipment and other intangible assets comprising the referrer relationship independently valued at date of acquisition.
The fair value of the consideration transferred at acquisition date for FSR was made up of the following components:
$'000 | |
Payment for 90% of the Issued Shares in the Entity | |
Cash | 13,961 |
Shares issued | 2,070 |
Deferred and contingent consideration payable | 1,382 |
Completion adjustmentii) | (793) |
16,620 | |
Assumed: | |
Net current assets acquired | (472) |
-Employee Entitlements | 53 |
-Make Good Provision | 54 |
Other intangible asset | |
- Referrer Relationship | (2,476) |
- Brand Name | (496) |
Recognition of Deferred Tax Asset | (66) |
Recognition of Deferred Tax Liability | 892 |
Fair value of net assets acquired | (2,511) |
Non-controlling interest | 251 |
Goodwill | 14,360 |
ii) The completion adjustment has been updated since 30 June 2020 to reflect the final acquisition accounting for Fowler
Simmons Radiology.
Since 31 December 2020 the company acquired the business and assets of Direct Radiology, a group comprising three clinics based in Melbourne, Victoria. For more details refer to Note 19 - Events Occurring after the Reporting Period.
Combinations for prior reporting period
The Group finalised the accounting of the acquisition of UniRadiology during the half-year ended 31 December 2019. At 30 June 2019 the group provisionally accounted for goodwill of $8.0 million. There were no new acquisitions during the period.
Date of | Purchase | Net Assets | Goodwill | Note | ||
acquisition | Business Name | State | consideration | Acquired | Reference | |
$000 | $000 | $000 | ||||
22 March 2019 | Uniradiology | VIC | 8,004 | 2,010 | 5,994 | ii) |
iii) The Group acquired the assets and liabilities of Uniradiology. The net assets include the plant and equipment and other intangible asset comprising the referrer relationship independently valued at date of acquisition.
16.
Contingencies
Rental Guarantees
The Group has an obligation to provide rental property guarantees when requested by the owners of rented premises which may be classed as a contingent liability unless supported by value for value specific deposits.
17.
Segment Information
The Group has one business segment which is the operation of diagnostic imaging facilities in Australia. The segment is defined by national registration available for diagnostic imaging. Senior management and the Board regularly review the Group's operating results to allocate resources and assess/review the
Group's performance as a whole. As the Group operates in a single business and geographic segment no further disclosures are required. Overseas controlled entities did not trade during the period.
18. Fair Value Measurement of Financial Instruments
The carrying amount of financial assets and financial liabilities, which are not measured at fair value in the statement of financial position, approximate their fair values.
19. Events Occurring after the Reporting Period
Subsequent to the end of the Reporting Period:
Acquisition
On 1 February 2021 the Group completed the acquisition of the business and assets of Direct Radiology, which operates diagnostic imaging clinics in Fairfield, Monbulk and South Melbourne in Victoria.
The consideration for the acquisition amounted to $12.65 million and was funded from cash reserves, existing bank debt facilities and $0.65 million in issued shares in the Company. The shares are to be held in voluntary escrow until 31 August 2023 and are subject to achieving a revenue target in FY23.
Dividend
The Company declared an interim dividend for the half-year ended 31 December 2020 of 0.5 cents per share (31 December 2019: 0.5 cents) with the maximum dividend payable of $5.1 million (31 December 2019: $3.8 million).
Other than the above, there have been no other matters or circumstances occurring subsequent to the end of the half-year that has significantly affected, or may significantly affect, the operations of the Group, the results of these operations, or the state of affairs of the Group in subsequent financial years.
Directors' Declaration
In the opinion of the Directors of Capitol Health Limited:
(a) the financial statements and notes set out on pages 5 to 19, are in accordance with the Corporations Act 2001, including:
(i) giving a true and fair view of the Group's financial position as at 31 December 2020 and of its performance for the half-year ended on that date; and
(ii)complying with Australian Accounting Standards and the Corporations Regulations 2001 and other mandatory professional reporting requirements; and
(b) there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.
Signed in accordance with a resolution of the Directors made pursuant to s.303 (5) of the Corporations Act 2001.
On behalf of the Directors
____________________________ Justin Walter
Managing Director and Chief Executive Officer Melbourne, Victoria
23 February 2021
Deloitte Touche Tohmatsu ABN 74 490 121 060
550 Bourke Street
Melbourne VIC 3000
GPO Box 78
Melbourne VIC 3001 Australia
Tel: +61 3 9671 7000
Fax: +61 3 9671 7001www.deloitte.com.au
Independent Auditor's Review Report to the members of Capitol Health Limited
Liability limited by a scheme approved under Professional Standards Legislation.
Member of Deloitte Asia Pacific Limited and the Deloitte Network
Attachments
- Original document
- Permalink
Disclaimer
Capitol Health Limited published this content on 23 February 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 February 2021 09:50:08 UTC.